Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study
Plasma cfDNA analysis using NGS is feasible and offers insights into alectinib resistance mechanisms. Early detection of resistance-associated mutations may guide personalized treatment strategies. Larger prospective studies are needed to validate these findings.
Authors
- Shingo Matsumoto (ORCID: https://orcid.org/0000-0003-2698-0839)
- Takuji Toyama (ORCID: https://orcid.org/0000-0002-3591-8327)
- Ryohei Katayama (ORCID: https://orcid.org/0000-0001-7394-895X)
- Akihiro Nishiyama (ORCID: https://orcid.org/0000-0002-4805-9787)
- S. Miyagi
- Shigeki Yoshiura
- Mitsunobu Matsumoto
- Shinji Takeuchi (ORCID: https://orcid.org/0000-0002-3779-1454)
- Koh Furugaki (ORCID: https://orcid.org/0009-0008-9626-2027)
- Hirotoshi Sakaguchi (ORCID: https://orcid.org/0000-0003-0236-1187)
- H Mizuta
- Atsushi Tajima
Institutions
- Kanazawa University (JP)
- Kanazawa University Hospital (JP)
- Kanazawa Medical University Hospital (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105574
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical